摘要
目的 观察达格列净对 2 型糖尿病(T2DM)合并心力衰竭患者急性心肌损伤的效果.方法 68 例T2DM合并心力衰竭患者分为观察组(36 例)和对照组(32 例);两组均使用心力衰竭基础治疗,观察组联用达格列净.比较两组心肌损伤标志物和炎症因子水平的变化、主要不良心血管事件(MACE)及心力衰竭复发再住院次数.结果 观察组氨基末端脑钠肽前体、高灵敏肌钙蛋白T、TNF-α、IL-1β、IL-6、C反应蛋白水平及MACE发生率、心力衰竭复发再次住院率明显低于对照组(P<0.01 或 0.05).结论 达格列净可减轻T2DM合并心力衰竭患者急性心肌损伤及炎症因子水平,改善心力衰竭.
Abstract
Objective To observe the effect of dapagliflozin on acute myocardial injury in patients with type 2 diabetes mellitus(T2DM)and heart failure.Methods Sixty-eight patients with T2DM and heart failure were treated with conventional anti-heart failure therapy(n=32,control group)or combined dapagliflozin(n=36,observation group).Myocardial injury markers,inflammatory cytokines,major adverse cardiovascular events(MACE),and rehospitalization of recurrent heart failure were compared between two groups.Results Compared with control group,levels of N-terminal pro-B-type natriuretic peptide(NT-proBNP),high sensitivity cardiac troponin T(Hs-TnT),TNF-α,IL-1β,IL-6,C-reactive protein(CRP),MACE,and rehospitalization of recurrent heart failure were lower in observation group(P<0.01 or 0.05).Conclusion Dapagliflozin can improve acute myocardial injury and inflammatory cytokines in patients with T2DM and heart failure.
基金项目
湛江市科技计划(2022A01187)
湛江市非资助科技攻关计划(2021B01026)
广东省医学科研项目(A2017494)
广东医科大学青年科研培育基金(2001/2XK22007)
维普
万方数据